Healthcare & Life Sciences: Drug Pricing Digest - January 2022 #3

Latham & Watkins LLP
Contact

Drug Pricing Initiatives: The pathway to Senate passage of H.R. 5376 (the Build Back Better Act, or BBBA) remains unclear. President Biden has suggested splitting up the BBBA and individually passing those provisions that have the support of the full Democratic caucus. Meanwhile, some Democratic Senators are pressing for passage of the bulk of such provisions in advance of President Biden’s State of the Union address on March 1, 2022. House Speaker Nancy Pelosi has said she expects efforts to focus on a single, but scaled-back BBBA bill. The BBBA’s drug pricing measures are reportedly backed by the full Democratic caucus, making it likely they will be included in efforts at passage. The BBBA, in its current form, is an approximately $2.2 trillion social safety net, climate, and tax bill that includes measures related to drug pricing and healthcare. The House of Representatives passed the BBBA on Nov. 19, 2021.

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Latham & Watkins LLP | Attorney Advertising

Written by:

Latham & Watkins LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Latham & Watkins LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide